Impact of depressive symptoms on motivation in persons with post-COVID-19 condition.

OBJECTIVE

The World Health Organization (WHO) has defined Post-COVID-19 Condition (PCC) as the onset of symptoms within three months after resolution of an acute SARS-CoV-2 infection, wherein symptoms persist for at least two months and cannot be explained by another medical/psychiatric condition. Persons living with PCC report debilitating symptoms including, but not limited to, depressive symptoms and motivational deficits. The aim of this post-hoc analysis was to evaluate the association between depressive symptoms and motivation in adults with PCC.

METHODS

We conducted a post-hoc analysis of an 8-week, double-blind, randomized, placebo-controlled trial evaluating adults (18 years or older) in Canada with WHO-defined PCC and cognitive symptoms. This post-hoc analysis is comprised of baseline data that evaluates the association between depressive symptom severity measured by the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16) and motivational systems measured by the Behavioral Inhibition System/Behavioral Activation System Questionnaire (BIS/BAS).

RESULTS

There was a statistically significant association between depressive symptoms and BIS ( = -0.041 95% CI [-0.066, -0.016], p<0.05), BAS reward responsiveness ( = 0.043 95% CI [0.012, 0.074], p<0.05), sex ( = -0.137 95% CI [-0.266, -0.008], p<0.05), and confirmed COVID-19 infection ( = 0.196 95% CI [0.061, 0.332], p<0.05).

CONCLUSIONS

Depressive symptoms were associated with motivational deficits in persons living with PCC. Optimizing treatment for depressive symptoms may potentially improve aspects of motivational impairment amongst persons with PCC. All patients presenting with MDD and a history of COVID-19 infection should be assessed for the presence of PCC.